论文部分内容阅读
目的 :观察骨吸收抑制剂羟乙膦酸钠对实验性高钙尿症的防治作用 ,并探讨其可能机制。 方法 :建立大鼠实验性高钙尿症模型 ,观察羟乙膦酸钠治疗后 2周和 4周的尿钙 ,Ca2 + / Cr,NAG/ Cr,以及肾和十二指肠 Ca2 + - ATP酶 (钙泵 )的变化。结果 :2周时尿钙 ,Ca2 + / Cr,血 AL P虽有所升高 ,但 4周时尿钙 ,Ca2 + / Cr,NAG/ Cr及血 AL P均显著下降 (P<0 .0 1) ,2 4h尿钙定量与尿 NAG/ Cr值呈正相关 ;而靶组织钙泵活性无显著改变。 结论 :骨吸收抑制剂具降尿钙和保肾作用 ,其机制不依赖钙泵活性的改变。
Objective: To observe the preventive and therapeutic effects of sodium etidronate, a bone resorption inhibitor, on experimental hypercalciuria and to explore its possible mechanism. Methods: The model of experimental hypercalciuria in rats was established. The levels of urinary calcium, Ca2 + / Cr, NAG / Cr and renal and duodenal Ca2 + - ATP were observed at 2 weeks and 4 weeks after treatment with etidronate. Changes in enzyme (calcium pump). Results: The levels of urinary calcium, Ca2 + / Cr and blood ALP increased at 2 weeks, but the levels of urinary Ca2 +, Ca2 + / Cr, NAG / Cr and ALP decreased significantly at 4 weeks (P <0. 0 1), 24 h urine calcium and urine NAG / Cr value was positively correlated; while the target tissue calcium pump activity did not change significantly. Conclusion: The bone resorption inhibitor has the effects of lowering the urinary calcium and protecting the kidney, and the mechanism does not depend on the change of calcium pump activity.